Guangzhou Keruite Pharmaceutical
Focus on the field of antineoplastic drugs
Guangzhou Keruite Pharmaceutical Co., Ltd. ("Keruite Pharmaceutical") is a subsidiary of Qixi Group, founded in 2013. It is a modern comprehensive pharmaceutical enterprise integrating R&D, production and marketing. The R&D center is located in Guangzhou High-tech Industrial Development Zone. The self-built factory is located in Yonghe Development Zone, Huangpu District, Guangzhou, covering an area of about 13,000 m2. There are four main buildings: oral solid preparation workshop, API workshop and supporting class A warehouse and environmental protection station.
After years of relentless efforts , the company has built a highly educated research team with strong technological strength, and established a sound GMP and EHS management system. At present, it has successfully overcome the technical barriers of more than ten kinds of antitumor drugs such as lenalidomide, erlotinib, imatinib and sunitinib, and developed API and FDF with its own production advantages.


Established in 2013

More than 20 company qualification certificates

More than 20 kinds of products (R & D)

More than 50 cooperation medical (scientific research) units

Custom Services

Comprehensive Quality Management System
We have professional quality management personnel who have the quality management capability from R&D to product launch.

Efficient Transformation Team
Implement project management to ensure a smooth process from transfer to industrialization with strict control measures.

Perfect Hardware Facilities
Laboratory testing equipment readily available, including gas liquid chromatograph, ultra-high performance liquid chromatograph, infrared spectrometer and other advanced equipment.

Rich Registration and Inspection Experience
Each year, applications for registration of 3 to 4 varieties were successfully submitted, and a number of supplementary studies were completed.
Blog

Interested in us?
Thank you very much for your support and attention to us all the time.